9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 Clonal analysis of the nature and specificity of cytotoxic T cells in melanoma patients Cutaneous Melanoma – Status of Knowledge and Future Perspective, Eds. U. Veronesi, N. Cascinelli and M. Santinami. Acad. Press, p.421-432
2. 2011 Ets-1 mediates up-regulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress Oncogene (Accepted for publication).
3. 2011 MEK-Independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720 Clinical Cancer Research 17:721-730
4. 2011 Contracting effects of Nutlin-3 on TRAIL- and Docetaxel-Induced apoptosis due to up-regulation of TRAIL-R2 and Mcl-1 in human melanoma cells Mol. Cancer Therapeutics 9(12):3363-3374
5. 2010 Targeting apoptotic pathways in melanoma Targeted Therapeutics in Melanoma. Editors Gajewski T and Hodi S, Humana Press 2010 (in press)
6. 2010 Nucleotide excision repair gene expression after Cisplatin treatment in melanoma. Cancer Research 70(20):7918-7926
7. 2010 TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis 15(10):1211-1222
8. 2010 Cystatin B inhibition of TRAIL-induced apoptosis is associated with protection of FLIP(L) from degradation by the E3 ligase Itch in human melanoma cells . Cell Death & Differentiation 17:1354-1367
9. 2010 contracting effects of Nutlin-3 on TRAIL- and Docetaxel-Induced apoptosis due to up-regulation of TRAIL-R2 and Mcl-1 in human melanoma cells Seminars in Oncology 37(5):517-523
10. 2010 Cell Death Dis 1, e69;doi:10.1038/cddis.2010.48 Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of BimS
11. 2010 A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.being treated with dacarbazine Molecular Cancer 9:69
12. 2010 Results of a multicenter, randomized, double-blind phase II/III study of lenalidomide in the treatment of pre-treated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146-154
13. 2010 Asia-Pacific Journal of Clinical Oncology 6(Suppl. 1):A2-A8 Immunotherapy of melanoma
14. 2009 Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs via XBP-1-mediated activation of Akt Neoplasia. 11(5):436-447. (IF: 5.191)
15. 2009 Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Letters 274 :40-46. (IF: 3.398)
16. 2009 Glucose-regulated protein 78 antagonizes cisplatin and Adriamycin in human melanoma cells. Carcinogenesis 30:197-204. (IF: 5.406)
17. 2009 O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with advanced melanoma treated with temozolomide alone or with lomeguatrib. British Journal of Cancer 100(8):1250-1256
18. 2009 Phase III randomized, placebo-controlled study of Sorafenib in combination with Carboplatin and Paclitaxel in second-line treatment in patients with unresectable stage III or stage IV melanoma. J . Clin. Oncol. 27:2823-2830.
19. 2009 2-Deoxy-D-Glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2 Molecular Cancer 8:122
20. 2009 Small molecules and targeted therapies in distant metastatic disease Ann. Oncol. Aug;20 Suppl 6:vi35-40. (IF: 4.935)
21. 2009 Immunotherapy of distant metastatic disease Ann. Oncol. Aug;20 Suppl 6:vi41-50. (IF: 4.935)
22. 2009 Biomarkers in Melanoma Ann. Oncol. Aug;20 Suppl 6:vi8-13. (IF: 4.935)
23. 2009 Utility of adjuvant systemic therapy in melanoma Ann. Oncol. Aug;20 Suppl 6:vi30-34. (IF: 4.935
24. 2009 Metabolic approaches to treatment of melanoma Clinical Cancer Research 15:6490-6494
25. 2009 Treatment combinations targeting apoptosis to improve immunotherapy of melanoma Cancer Immunology Immunotherapy 58(11):1751-1761.
26. 2009 Lactate dehydrogenase 5 (LDH-5) expression increases with progression in melanoma and is associated with Bcl-XL and Mcl-1 but not Bcl-2 expression. Modern Pathology 23:45-53. (IF: 4.678)
27. 2009 A randomized phase 2 study of Etaracizumab, a monoclonal antibody against integrin αV β3, + Dacarbazine in patients with stage IV metastatic melanoma. Cancer 116:1526-1534. (IF: 5.238)
28. 2009 preference values for advanced melanoma health states in the United Kingdom and Australia. British Journal of Cancer 101:387-389 (IF: 4.846)
29. 2009 Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic Obatoclax Neoplasia 11(9):945-955. (IF: 5.191)
30. 2009 Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology. 54(4):462-470. (IF: 4.131)
31. 2008 Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma Pigment Cell & Melanoma Research 21(3):358-367.
32. 2008 Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis 13(12): 1505-1512.
33. 2008 Apoptosis 13(12): 1505-1512. Melanoma Research 18(6):40411. (2.225)
34. 2008 therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126. (IF: 28.628)
35. 2008 Up-Regulation of Mcl-1 is Critical for Survival of Human Melanoma Cells Upon ER Stress. Cancer Research 68(16)6708-6717. (IF: 7.672)
36. 2008 to ER stress as a driver of malignancy and resistance to therapy in human melanoma. . Pigment Cell and Melanoma Research 21(3):358-367. (IF: 4.288)
37. 2008 Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. Melanoma Research 18(2):161-162. (IF: 2.225)
38. 2008 ). Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol. Immunotherapy 57:1037-1051. (IF: 4.313)
39. 2008 Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III β-tubulin levels. FEBS Letters 582:267-272. (IF: 3.263)
40. 2008 Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells. Anti-Cancer Drugs 19(2):159-166. (IF: 2.245)
41. 2008 Inhibition of ER stress-induced apoptosis of human melanoma cells by the ARC protein. Cancer Research 68(3):834-842. (IF: 7.672)
42. 2008 Small molecular weight variants of p53 are expressed in human melanoma cells and are differentially regulated by cisplatin. Clinical Cancer Research 14(6):1659-1668. (IF: 6.250)
43. 2008 Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anti-Cancer Drugs 19(2):189-200. (IF: 2.245)
44. 2008 Chapter 33: Adjuvant therapy for cutaneous melanoma Fourth Edition. Eds: Balch, C.M. Lippincott, NY
45. 2007 Docetaxel- induced Apoptosis in Melanoma Cells is dependent on Activation of Caspase 2 Mol Cancer Therapeutics 6:752-761. (IF: 4.800).
46. 2007 Docetaxel-induced apoptosis of human melanoma is mediated by activation of JNK and inhibited by the MAPKinase ERK1/2 pathway. Clinical Cancer Research 13:1308-1314. (IF: 6.250)
47. 2007 A randomised trial of the combination of lomeguatrib and temozolomide versus temozolomide alone in chemo-naïve patients with metastatic cutaneous melanoma. J. Clinical Oncology 25:2540-2545. (IF: 13.598)
48. 2007 Tunicamycin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67(12):5880-5888. (IF: 7.672).
49. 2007 Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clinical Cancer Research 13(16) 4934-4942. (IF: 6.250)
50. 2007 Inhibition of MEK/ERK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis by enhancing caspase-4 activation. Cancer Res. 67(20):9750-9761. (IF: 7.672.)
51. 2007 sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. Carcinogenesis 28:2328-2336. (IF: 5.406)
52. 2007 Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Molecular Cancer Research 5:1073-1081. (IF: 4.759)
53. 2007 Temozolomide induces senescence but not apoptosis in human melanoma cells. British Journal of Cancer 97:1225-1233. (IF: 4.459)
54. 2007 Overcoming resistance to apoptosis in cancer therapy Programmed Cell Death in Cancer Progression and Therapy. Eds: Khosravi-Far, R. and White, E.
55. 2007 Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma Modern Pathology 20:416-426. (IF: 4.286)
56. 2006 Cross resistance of melanoma to trail-induced apoptosis and chemotherapy Update on Cancer Therapeutics 1:435-441. (IF: Online journal
57. 2006 Current strategies in overcoming resistance of cancer cells to apoptosis. Melanoma as a model International Review of Cytology – A Survey of Cell Biology. Ed: Jeon, K.W. Elsevier, California. P131-158.
58. 2006 Apoptosis and Melanoma. How new insights are effecting the development of new therapies for melanoma current Opinion in Oncology 18:189-196. (IF: 4.544)
59. 2006 Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 11(12):2251-2265 (IF: 4.497)
60. 2006 Involvement of BH3 only proapoptotic proteins in mitochondrial dependent Phenoxodiol induced apoptosis of human melanoma cells. Anticancer Drugs 17(10):1151-1161 (IF: 1.97).
61. 2006 Bcl-2 antisense (Oblimersen Sodium) plus Dacarbazine in patients with advanced melanoma. J. Clin. Oncol. 24:4738-4745.
62. 2006 Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Human Pathology 37:1286-1294 (IF: 3.043)
63. 2006 Human melanoma cells selected for resistance to apoptosis by prolonged exposure to TRAIL are more vulnerable to necrotic cell death induced by Cisplatin Clin. Cancer Res. 12(4):1355-1364. (IF: 6.250)
64. 2005 Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Letters 579(9):1940-1944. (IF: 3.263)
65. 2005 Activation of the extracellular-signal related kinase (ERK) pathway in human melanoma. J. Clin. Pathology 58(11):1163-1169. (IF: 2.245)
66. 2005 Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma Invest. New Drugs 23(3):253-6. (IF: 2.41)
67. 2005 Cross resistance of melanoma to TRAIL induced apoptosis and chemotherapy Cancer Chemotherapy & Biological Response Modifiers Annual.
68. 2005 Immunotherapy of Melanoma – Past, Present and Future Cancer Forum. The Cancer Council, Australia
69. 2005 Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV melanoma. Cancer Immunology Immunotherapy 54(3): 208-218. (IF: 4.313)
70. 2005 Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Molecular Cancer Therapeutics 4(4):668-76. (IF: 4.800)
71. 2005 Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research 15:45-51. (IF: 2.225)
72. 2005 Is Apaf-1 expression frequently abrogated in melanoma? (Letter) Cell Death & Differentiation 12(6):680-1. (IF: 8.254)
73. 2004 Immunotherapy of non-resected melanoma Textbook of Melanoma. Eds. Thompson, JF, Morton, DL, & Kroon, BBR. Martin Dunitz/Taylor and Francis. London. 57:559.
74. 2004 Immunotherapy of melanoma: principles Textbook of Melanoma. Eds. Thompson, JF, Morton, DL, & Kroon, BBR. Martin Dunitz/Taylor and Francis. London. 54:559.
75. 2004 Vaccinia viral lysates in immunotherapy of melanoma Virus Therapy of Human Cancers. Eds: Sinkovics, J.G. and Horvath, J.C. Marcel Dekker, Inc. New York. Pages 691-712.
76. 2004 Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma Pathology 36(6):561-565. (IF: 3.043)
77. 2004 Ingenol 3-angelate induces dual modes of cell death and differentially regulates TRAIL-induced apoptosis in melanoma cells Molecular Cancer Therapeutics 3:1651-1658. (IF: 4.800)
78. 2004 Rapid downregulation of antigen processing enzymes in exi vivo generated human monocyte derived dendritic cells occur endogenously in extended cultures. Immunol. Immunol. Cell Biol. 82(3):239-246. (IF: 1.854)
79. 2004 Microarray expression profiling in melanoma reveals a BRAF mutation signature Oncogene 23(23): 4060-7. (IF: 6.444) (C: 2)
80. 2004 The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3(4):425-435. (IF: 5.581)
81. 2004 Translational control of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor expression in melanoma cells. J. Biol. Chem. 279:10606-10614. (IF: 6.482)
82. 2004 Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21. Clinical Cancer Research 10. (IF: 6.250) (C: 3)
83. 2004 Vaccinia viral lysates in immunotherapy of melanoma Virus Therapy of Human Cancers. Eds: Sinkovics, J.G. and Horvath, J.C. Marcel Dekker, Inc. New York. Pages 691-712
84. 2004 Regulation of TRAIL receptor expression in human melanoma Death Receptors in Human Cancer. Eds: El-Deiry, W.S. Humana Press. New Jersey. Pages 175-187
85. 2004 Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma Cancer Immunol. Immunother. 53:125-134, 2004. (IF: 4.086) (C: 3)
86. 2004 Staurosporine induces apoptosis of melanoma by both caspase dependent and independent apoptotic pathways. Molecular Cancer Therapeutics 3(2): 187-197. (IF: 4.800) (C: 1)
87. 2004 Immunotherapy of non-resected melanoma Textbook of Melanoma. Eds: Thompson, J.F., Morton, D.L. and Kroon, BBR. Martin Dunitz/Taylor and Francis. London. 57:559
88. 2004 Adjuvant therapy for high-risk primary melanoma and resected metastatic melanoma Textbook of Melanoma. Eds: Thompson, J.F., Morton, D.L. and Kroon. BBR. Martin Dunitz/Taylor and Francis. London. 55:573
89. 2004 Immunotherapy of melanoma: principles Textbook of Melanoma. Eds: Thompson, J.F., Morton, D.L. and Kroon. BBR. Martin Dunitz/Taylor and Francis. London. 54:559.
90. 2004 The history and future of melanoma staging Journal of Surgical Oncology 86(4):224-235
91. 2004 Regulation of TRAIL receptor expression in human melanoma : Death Receptors in Human Cancer. Eds: El-Deiry, W.S. Human Press. New Jersey, pages 175-187.
92. 2004 Adjuvant therapy for high-risk primary melanoma and resected metastatic melanoma Textbook of Melanoma. Eds: Thompson, JF, Morton, DL, & Kroon BBR. Martin Dunitz/Taylor and Francis. London. 55:573
93. 2003 Overcoming resistance of melanoma cells to apoptosis Journal of Cellular Physiology 196:9-18. (IF: 5.463) (C: 10
94. 2003 The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF related apoptosis inducing ligand (TRAIL) induced apoptosis Biochemical Pharmacology 66:1537-1545. (IF: 2.993) (C: 5)
95. 2003 Adjuvant therapy for high risk primary and resected metastatic melanoma Internal Medicine Journal 33:33-43.
96. 2003 Resistance of follicular lymphoma cells to chemotherapy is more than just Bcl-2 Cancer Biology & Therapy 2(5):541-3. (IF: 3.024
97. 2003 Adjuvant therapy for high risk primary and resected metastatic melanoma Internal Medicine Journal 33:33-43. (IF: 0.552) (C: 5)
98. 2003 Overcoming resistance of melanoma cells to apoptosis Journal of Cellular Physiology 196:9-18
99. 2003 Activation of ERK1/2 protects melanoma cells from TRAIL induced apoptosis by inhibiting SMAC/diablo release from mitochondria Oncogene 22:2869-2881. (IF: 6.495) (C: 5)
100. 2003 Association of increased levels of heavy chain ferritin with increased CD4+CD25+ regulatory T cells in patients with melanomaAssociation of increased levels of heavy chain ferritin with increased CD4+CD25+ regulatory T cells in patients with melanoma Clinical Cancer Research 9:2551-2559. (IF: 6.511) (C:1)
101. 2002 Adjuvant immunotherapy of patients with high risk melanoma with vaccinia viral lysates of melanoma. Results of a randomised trial J Clin Oncol 20:4181-4190. (IF: 10.864) (C: 12)
102. 2002 Immunotherapy World Cancer Report. Eds: Stewart, B.W. IARC 210-214
103. 2002 “Immunotherapy” World Cancer Report. Eds: Stewart, B.W. IARC 210-214
104. 2002 Advances in non-surgical treatment of melanoma . Expert Opin. Investig. Drugs 11(1):75-85. (IF: 3.117) (C: 4)
105. 2002 Heavy chain ferritin activates regulatory T cells by cells by induction of changes in dendritic cells Blood 99:3326-3334. (IF: 10.120) (C: 13)
106. 2002 Advances in non-surgical treatment of melanoma Expert Opinion on Investigational Drugs 11:75-85
107. 2002 A randomised trial of skin photography as an aid to screening skin lesions in older males J. Med. Screening 9:128-132. (IF: 1.867) (C: 4)
108. 2001 Will vaccines really work for melanoma? “Melanoma: Critical Debates” Eds: Newton-Bishop and Gore. Blackwell Science (In press)
109. 2001 Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1 Int. J. Cancer 94(4):551-557. (IF: 4.375) (C: 11)
110. 2001 How melanoma cells evade TRAIL induced apoptosis Nature Reviews Cancer 1:142-150. (IF: 33.954) (C: 36)
111. 2001 TRAIL induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria Cancer Research 61:7339-7348. (IF: 8.649) (C: 66)
112. 2001 Relative Resistance of fresh isolates of melanoma to TRAIL induced apoptosis. Clinical Cancer Research 7:966S-973S. (IF: 6.511) (C: 19)
113. 2001 The role of NF-kB in TRAIL induced apoptosis of melanoma cells. J. Immunol. 166:5337-5345. (IF: 6.702) (C: 36)
114. 2001 How melanoma cells evade TRAIL induced apoptosis Nature Reviews Cancer 1:142-150
115. 2000 Differential localization and regulation of death and decoy receptors for TRAIL in human melanoma cells J. Immunol. 164:3961-3970. (IF: 6.702) (C: 70)
116. 2000 Utility of tests for circulating melanoma cells (CMCs), in identifying patients who develop recurrent melanoma Recent Results in Cancer Research 158:211-230
117. 2000 Immunologically mediated tumor cell apoptosis. The role of TRAIL in T cell and cytokine mediated responses to melanoma Forum 10:243-252. (C: 4)
118. 2000 TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria J. Immunol. 165:5612-5620. (IF: 6.702) (C: 37)
119. 2000 Mechanisms of resistance of normal cells to TRAIL induced apoptosis varies between different cell types FEBS Letters 482:193-199. (IF: 3.609) (C: 66)
120. 2000 Participation of older males in a study on photography as an aid to early detection of melanoma Aust. N.Z. J. Public Health 24:615-618. (C: 5)
121. 2000 Utility of tests for circulating melanoma cells (CMCs), in identifying patients who develop recurrent melanoma Recent Results in Cancer Research 158:211-230.
122. 2000 Will vaccines really work for melanoma Melanoma: Critical Debates. Eds. Newton-Bishop and Gore. Blackwell Science (In press)
123. 1999 Expression of catenins and p120cas in melanocytic naevi and cutaneous melanoma: deficient a-catenin expression is associated with melanoma progression Pathology 31:239-246
124. 1999 Advances in management of melanoma A. & N.Z. J. Med. 29:292-299
125. 1999 Impediments to successful immunotherapy Pharmacology and Therapeutics 81:111-119
126. 1999 Relation of TRAIL receptor and FLIP expression to TRAIL induced apoptosis of melanoma Cancer Research 59:2747-2753
127. 1999 Cancer vaccines in therapy of cancer Primer on Tumor Immunology. Eds: Parmiani, G. and Lotze, M. Harwood Academic Press. (In press).
128. 1999 MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared to locoregional metastases J. Clin. Oncol. 17:2562-2572
129. 1999 Examination of the utility of assays for S100b in prediction of recurrence from melanoma. Melanoma Research 9:1-11
130. 1999 Assessing the perceived needs of patients attending an outpatient melanoma clinic J. Psychosocial Oncology 17:101-118
131. 1999 The chemoresistance of human malignant melanoma: an update Melanoma Research 9:1-8
132. 1998 Cancer vaccines in therapy of cancer Primer on Tumor Immunology. Eds. Parmiani, G. and Lotze, M. Harwood Academic Press
133. 1998 Impediments to Successful Immunotherapy Pharmacology & Therapeutics 81:111-119
134. 1998 A novel monoclonal antibody to human melanoma-associated antigen CD63/ME491 recognizes a new epitope both in primary and metastatic melanoma Hybridoma 17:355-364.
135. 1998 CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95 Int J Cancer 75:384-390
136. 1998 Revising interferons - prodigies among the cytokines Today’s Life Science, November/December: 37-43
137. 1998 General practitioner screening for melanoma: sensitivity, specificity, and effect of training J. Med. Screening 5:156-161
138. 1998 TRAIL induces apoptosis in Fas ligand resistant melanoma cells and mediates CD4 T cell killing of target cells J. Immunol. 161:2195-2200. (IF: 6.702) (C: 144)
139. 1998 ) Presentation of older people with thick melanoma is associated with failure to notice changes of melanoma, as well as the site and histological type of their melanoma Med J Aust 169:410-414
140. 1998 PCR detection of melanoma cells in the circulation. Relation to clinical stage, surgical treatment and recurrence from melanoma J Clin Oncol 16:1760-1769
141. 1997 Clinical Applications of the Interferons Eds. Penny, R. and Stuart-Harris, R. Chapman and Hall, London.p. 169-183
142. 1997 Contrasting effects of T cell growth factors on T cell responses to melanoma in vitro Cancer Immunol. Immunother. 43:345-354
143. 1997 Regulation of adhesion and motility by the CD63 molecule in a human cell line J. Immunol. 158:3353-3358
144. 1997 Examination of the ability of people to identify early changes of melanoma in computer altered pigmented skin lesions Archives of Dermatology 133:301-311
145. 1997 Melanoma Vaccines. Prospects for the treatment of melanoma Expert Opinion On Investigational Drugs 6:267-277
146. 1997 Remission of transplanted melanoma - clinical course and tumour cell characterisation Clinical Transplantation 11(6):565-568
147. 1997 Immunogenicity of CD63 in a patient with melanoma Melanoma Research 7(Suppl 2):5161-5168
148. 1997 Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3g J Biol. Chem. 272:28779-28785
149. 1997 Recombinant interferon-a2a plus 5-fluorouracil for the treatment of metastatic melanoma Melanoma Research 7:513-516
150. 1997 Interferon in skin tumors. Melanoma and basal cell carcinoma. Clinical Applications of the Interferons. Eds. Penny, R. and Stuart-Harris, R. Chapman and Hall, London. P. 1699-183.
151. 1997 Foreword to “Current Status of Melanoma Vaccines” The Oncology Review. Issue 14.
152. 1996 Expression of the tumour suppressor genes p15 and p16 in malignant melanoma Melanoma Research 6:285-289
153. 1996 CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with ß1 integrins in human melanoma Biochem Biophys Res Commun 222:13-18
154. 1996 Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF Melanoma Research 6:247-255
155. 1996 Melanoma peptides in treatment of melanoma Life Science 8:34-38
156. 1996 Expression of the costimulatory molecule CD40 on melanoma cells Int. J. Cancer 68:795-801
157. 1996 Naevi and pigmentary characteristics as risk factors for melanoma in a high risk population: a case-control study in New South Wales, Australia . Int. J. Cancer 67:485-491
158. 1996 Detection and quantitation of melanoma cells in the circulation of patients Melanoma Research 6(1):45-54
159. 1996 Melanoma peptides in treatment of melanoma Life Science, 8:34-38.
160. 1995 Evaluation of the effect of an educational brochure on knowledge and early detection of melanoma Aust. J. Public Health 19:270-274
161. 1995 Solar ultraviolet radiation and the risk of infectious disease: Summary of a workshop Photochemistry and Photobiology 61:223-247
162. 1995 Suppression of human melanoma cell growth and metastasis by the melanoma associated antigen CD63 (ME491). Int. J. Cancer 62:631-635
163. 1994 Immunohistological examination of the relation between metastatic potential and expression of adhesion molecules and "selectins" on melanoma cells Pathology 26:6-15.
164. 1994 Melanoma Vaccines Current Status and Future Prospects. Drugs, 47:373-382
165. 1994 Risk Factors for presentation with thick primary melanoma include older age, male sex, smoking and may include occupation in certain industries Epidemiologic Aspects of Malignant Melanoma. Ed. Gallagher, R.P., Elwood, J.M. Kluwer Academic Publishers, Boston. p. 273-288.
166. 1994 Production of IL-10 by melanoma cells. Examination of its role in immunosuppression mediated by melanoma Int. J. Cancer 56:755-760
167. 1994 HLA-A1 restricted recognition of melanoma by cytotoxic T cells Cancer Immunol. and Immunother. 34:385-393
168. 1994 Reliability of naevus counts in identifying individuals at high risk of malignant melanoma Brit. J. Dermatol. 130:51-56
169. 1994 Melanoma Vaccines. Current Status and Future Prospects Drugs 47:373-382
170. 1994 Expression of the costimulatory molecule B7 on melanoma cells Int. J. Cancer 58:527-532
171. 1993 Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma Eur. J. Cancer 29A(12):1731-1734
172. 1993 Cellular therapy Current Opinion in Oncology 5:1049-1054
173. 1993 Cellular Therapy Current Opinion in Oncology, 5:1049-1054
174. 1993 The current status of immunotherapy for melanoma Cancer Forum, July, 1993, 101-106
175. 1993 Vaccinia viral lysates in treatment of melanoma Biological approaches to Cancer Treatment: Biomodulation. Ed. Mitchell, M.S. McGraw Hill, New York. p. 302-325
176. 1993 An analysis of a melanoma epidemic Int. J. Cancer 55:765-770
177. 1993 The current status of immunotherapy for melanoma Cancer Forum, July, 1993. 100-106
178. 1993 Expression of the neuroglandular antigen and analogues in melanoma. CD9 and MHC class I antigens appear inversely related to metastatic potential of melanoma Int. J. Cancer 54:37-43
179. 1993 Evaluation of vaccinia viral lysates as therapeutic vaccines in treatment of melanoma Specific Immunotherapy of Cancer with Vaccines. Ed. Bystryn, J.C., Ferrone, S. and Livingston, P. Ann NY Acad. Sci., Vol. 690, p. 167-178
180. 1993 Interferon alpha-2a does not improve response or survival when combined with dacarbazine alone in metastatic malignant melanoma: Results of a multi-institutional Australian randomised trial Melanoma Res. 3:133-138
181. 1992 Development of an in vitro system for the analysis of ultraviolet radiation induced suppression of natural killer cell activity Photochem. & Photobiology 57:279-284
182. 1992 Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma World J. Surg. 16:251-260
183. 1992 Examination of the scientific basis for vaccines in treatment of melanoma Vaccine Research 1:357-372
184. 1992 Examination of the scientific basis for vaccines in treatment of melanoma Vaccine Research 1:357-372
185. 1992 MHC restricted responses of CD8+ and CD4+ T cell clones from regional lymph nodes of melanoma patients Int. J. Cancer 51:218-224. (IF: 4.375) (C: 37)
186. 1992 Cytokines in melanoma therapy Interferons and Cytokines, 21:6-11.
187. 1992 Risk factors for presentation with thick primary melanoma include older age, male sex, smoking and may include occupation in certain industries Epidemiologic Aspects of Melanoma. Ed. Gallagher, R.P., Kluwer Academic Publishers
188. 1992 Cytokines in melanoma therapy Interferons and Cytokines 21:6-11
189. 1991 Factors related to presentation of patients with thick primary melanomas Med. J. Aust. 154:583-7.
190. 1991 Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC. Long term follow up of two phase II studies Brit. J. Haematol. Supplement 1, 79:60-66
191. 1991 Non-surgical treatment of melanoma Australian Prescriber, 14:36-37
192. 1991 Immunotherapy of malignant melanoma Cancer Forum, 14:24-31
193. 1990 Identification of antigens recognized by T cells Focus on Laboratory Methods in Immunology. Ed. Zola, H. CRC Press Inc. p. 185-193
194. 1990 Identification of antigens recognized by T cells Focus on Laboratory Methods in Immunology, Ed. Zola, H. CRC Press Inc., p.185-194
195. 1990 Characterization of melanoma antigens recognized by human T cells Cellular Immunity and Immunotherapy of Cancer, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume*. Ed. Lotze, M.T. and Finn, O.J. Wiley-Liss, Inc., New York, NY. p. 343-349
196. 1990 Current status of active specific immunotherapy of melanoma Therapy of advanced malignant melanoma, Ed. Rumpke, P. S. Karger, AG Basel, p.183-200
197. 1990 status of active specific immunotherapy of melanoma Therapy of advanced malignant melanoma. Ed. Rumpke, P. S. Karger, AG Basel. p. 183-200
198. 1990 Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells Int. J. Cancer 46:612-617
199. 1990 Characterization of melanoma antigens recognized by human T cells Cellular Immunity and Immunotherapy of Cancer, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume*. Ed. Lotze, M.T. and Finn, O.J. Wiley-Liss, Inc., New York, NY. P.343-349
200. 1990 Fc receptors as mediators of MHC-unrestricted lysis by activated type 2 T cells 6th Int. NK Workshop, Ed. Schmidt, R.E. S. Karger, AG Basel. P.94-98
201. 1990 Ganglioside antigens in tissue sections of skin, naevi and melanoma – implications for treatment of melanoma Cancer Treatment and Research. Melanoma Research: Genetics, Growth Factors, Metastases, and Antigens. Ed. Nathanson, L. Kluwer Academic Publishers. P.137-151
202. 1990 Immunotherapy of malignant melanoma Cancer Forum 14:24-31
203. 1990 Biological agents in treatment of cancer A. & N.Z. J. Med. 20:85-98
204. 1990 Immunohistological relation between DR antigen expression on melanoma cells and infiltration by CD8+ T cells Pathology 22:133-139
205. 1990 Vaccinia viral lysates in treatment of melanoma Biological Approaches to Cancer Treatment: Biomodulation. Ed. Mitchell, M.S. McGraw Hill, New York. P.302-325
206. 1990 Fc receptors as mediators of MHC-unrestricted lysis by activated type 2 T cells 6th Int. NK Workshop. Ed. Schmidt, R.E. S. Karger, AG Basel. p. 94-98
207. 1989 Photochemistry and Photobiology 61:223-247 Pigment Cell Res. 2:281-285
208. 1989 Preclinical and phase I studies of monoclonal antibodies in melanoma. Application to Boron neutron capture therapy of melanoma Pigment Cell Res. 2:264-272.
209. 1989 "Natural immunity" mediated by activated cytotoxic T lymphocytes Natural Immunity. Ed. Nelson, D.S. Acad. Press, 123-146
210. 1989 The role of protein kinase C (PKC) intracellular calcium and cyclic nucleotides in the augmentation of lymphocyte responses by monoclonal antibodies to the gangliosides GD3 and GD2 Cell. Immunol. 119:263-278
211. 1989 Potentiation of interleukin 2 (IL2) production and binding of IL2 by monoclonal antibodies to the gangliosides GD3 and GD2 Cancer Immunol. Immunotherapy 29(2):109-117
212. 1989 “Natural immunity” mediated by activated cytotoxic T lymphocytes Natural Immunity, Ed. Nelson, D.S. Acad. Press, p.123-146.
213. 1989 Preclinical and phase I studies of monoclonal antibodies in melanoma. Application to Boron neutron capture therapy of melanoma Pigment Cell Res., 2(4):264-272.
214. 1989 Monoclonal antibodies as immunomodulating agents in the treatment of melanoma. In: Human Melanoma . Immunology, Diagnostics and Therapy, Ed. Ferrone, S. Springer Verlag, N.Y., p.387-396
215. 1989 of immunity to human neoplasms Current Opinions in Immunology, Vol. 1, No. 5, Cancer and Immunology. Ed. Moore, M., Current Science, Alden Press, Oxford, p.895-899
216. 1989 Biological agents in treatment of cancer Aust. N.Z. J. Med., 20:85-98
217. 1989 Detection of immunity to human neoplasms Current Opinion in Immunology 1:895-899
218. 1988 Suppression of natural killer cell activity in humans by radiation from solarium lamps depleted of UVB J. Invest. Dermatol. 90:305-312.
219. 1988 DNA ploidy in thin melanoma Pathology 20:243-246
220. 1988 Western blot analysis of melanoma antigens recognized by T lymphocytes J. Natl. Canc. Inst. 80:826-835. (IF: 13.844) (C: 22)
221. 1988 Expression of the gangliosides GD3 and GD2 on lymphocytes in tissue sections of melanoma Pathology 21:51-58
222. 1988 Expression of the Gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma Int. J. Cancer 41:336-343
223. 1987 Immunohistological evaluation of MHC Class I and II antigen expression on naevi and melanoma - relation to biology of melanoma Pathology 19:339-346
224. 1987 Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with Dacarbazine (DTIC) in advanced malignant melanoma (MM) "Progress in Chemotherapy". Anticancer Section. Ed. B Berkarda, Istanbul, and H.P. Kuemmerle, Munich/Tokyo/Shanghai
225. 1987 Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC Int. J. Cancer Supplement 1, 31-35
226. 1987 Evidence that treatment with vaccinia melanoma cell lysates may improve survival in patients with Stage II melanoma Cancer Immunol. Immunotherapy 25(3): 257-265
227. 1987 Factors influencing the generation of "non specific" MHC unrestricted cytotoxic T cells and receptors involved in their activity. Immunol. Today 8:233-239
228. 1987 Analysis of the effect of a sunscreen agent on the suppression of natural killer cell activity induced in human subjects by radiation from solarium lamps J. Invest. Dermatol. 88:271-276
229. 1987 Clonal analysis of the nature and specificity of cytotoxic T cells in melanoma patients. In “Cutaneous Melanoma – Status of Knowledge and Future Perspective” Eds. U. Veronesi, N. Cascinelli and M. Santinami Acad. Press 421-432
230. 1987 Factors influencing the generation of “non specific” MHC unrestricted cytotoxic T cells and receptors involved in their activity Immunol. Today 8:233-239
231. 1986 The evolving role of recombinant alpha interferons in the treatment of malignancies A. & N.Z. J. Med. 16:425-437
232. 1986 Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures Cancer Immunol. Immunother. 22:15-23
233. 1986 Comparative study on the effects of recombinant alpha 2 interferon on immune function in patients with disseminated melanoma J. Biol. Resp. Mod. 5:236-249
234. 1986 Effects of electromagnetic radiation on the immune system in mice and man. EOS J Immunol. And Immunopharmacol. 6:216-222
235. 1986 The evolving role of recombinant alpha interferons in the treatment of malignancies Aust. & N.Z. J. Med., 16:425-437
236. 1986 Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies against ganglioside GD3 Cancer Immunol. Immunotherapy 15:22-28.
237. 1986 Potentiation of interleukin 2, phytohemagglutin and T3 monoclonal antibody (M.Ab) induced lymphocyte responses by M.Abs to GD3 Cancer Res. 46:6083-6090. (IF: 8.649) (C: 77)
238. 1986 Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects of cell mediated cytotoxicity and leukocyte dependent antibody activity Cancer Immunol. Immunother. 22:221-231.
239. 1986 Recombinant interferon alpha (2A) combined with dacarbazine in treatment of metastatic melanoma 1986 ISIR-TNO Meeting
240. 1986 Immunological effects of recombinant interferon alpha 2A (rIFN-a2A) in patients with disseminated melanoma Cancer 57:1292-1300.
241. 1986 Phase II study of recombinant alpha-2 interferon in advanced malignant melanoma J. Interferon Res. 6:01-04
242. 1985 Current status of adjuvant therapy Cutaneous Melanoma. Clinical Management and Treatment Results Worldwide, Eds. Balch and Milton, J.B. Lippincott Co., Philadelphia, p.197-218
243. 1985 Review of melanoma antigens recognized by monoclonal antibodies. Their functional significance and application in diagnosis and treatment of melanoma Pathology 17:346-354
244. 1985 Effects of recombinant leukocyte interferon (rIFN-aA) on tumour growth and immune responses in patients with metastatic melanoma Br. J. Cancer 51:815-826.
245. 1985 Current research on immunopathology of melanoma: Analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma Pathology 17, 385-391
246. 1985 Review of melanoma antigens recognized by monoclonal antibodies. Their functional significance and applications in diagnosis and treatment of melanoma Pathology, 17:346-354
247. 1984 The synthesis of vitamin D metabolites by human melanoma cells J. Clin. Endocrinol. 57:76-84
248. 1984 Current status and future prospects for adjuvant therapy of melanoma Aust. N.Z. J. Surg. 54:303-316
249. 1984 No evidence for an association between natural killer cell activity and prognosis in melanoma patients Natural Immunity and Cell Growth Regulation 3:87-94
250. 1984 Effect of Isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo Int. J. Immunopharm. 6:315-320
251. 1984 Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells Int. J. Immunopharm. 6:321-328
252. 1983 Inhibition of interleukin 2 production by factors released from tumour cells J. Immunol. 131:2837.
253. 1983 Prognostic significance of leukocyte dependent antibody activity in melanoma patients. J. Natl. Canc. Inst. 71:45-53.
254. 1983 Clearance of systemically administered interleukin 2 (IL2) from the circulation of human subjects Brit. J. Cancer 47:123-133
255. 1983 Expression of Thy-1 antigen on human melanoma cells Int. J. Cancer 32:21-25
256. 1983 Immunological effects of solarium exposure in human subjects Lancet 545-548
257. 1983 Alteration of T cell subsets and incubation of suppressor T cell activity in normal subjects following exposure to sunlight J. Immunol. 31:171-174
258. 1983 Immunological effects of radiation from solarium lamps and the sun. Editorial Comment Med. J. Aust. August 20, 159-160
259. 1983 Effects of smoking on the immune system. Follow-up studies on normal subjects after cessation of smoking Effects of smoking on the immune system. Follow-up studies on normal subjects after cessation of smoking
260. 1983 Association of Sjogren’s syndrome with C4 deficiency defective reticulo-endothelial function and circulating immune complexes Clin. Exp. Immunol. 52:551-560
261. 1982 Immunotherapy of leukaemia “Leukaemia”. Eds. Gunz and Henderson, Grune and Stratton, p. 543-556
262. 1982 Deficient natural killer cell activity in a patient with Fanconi’s anaemia and squamous cell carcinoma. Association with defect in interferon release Clin. Exp. Immunol. 48:205
263. 1982 Analysis of the relation between natural killer cell activity and histologic features of lymphocyte infiltration and partial regression of the primary tumour in melanoma patients Cancer Research 42(1):363-368
264. 1982 Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma Oncodevelopmental Biology and Medicine 3:1-12
265. 1982 Tumour related changes and prognostic significance of natural killer cell activity in melanoma patients “Natural Cell Mediate Immunity”, Vol. 2. Ed. Herberman, R.B., Acad. Press, N.Y., p. 1167-1174
266. 1982 The nature and significance of melanoma antigens recognized by human subjects “Melanoma Antigens and Antibodies”. Eds. Ferrone and Reisfeld, Plenum Press, New York, p. 187-209
267. 1982 Tumour related changes and prognostic significance of natural killer cell activity in melanoma patients Natural Cell Mediated Immunity, Vol. 2, Ed. Herberman, Acad. Press, New York, p.1167-1174.
268. 1982 The nature and significance of melanoma antigens recognized by human subjects Melanoma Antigens and Antibodies, Eds. Ferrone and Reisfeld, Plenum Press, New York, p.187-209
269. 1981 Characterization of antigens recognized by natural killer cells in cell culture supernatants Brit. J. Cancer 43:5
270. 1981 Inhibition of suppressor T cells in pokeweed mitogen stimulated cultures of T and B cells by levamisole in vitro and in vivo Clin. Exp. Immunol. 46:360
271. 1981 Suppressor cell activity in melanoma patients. I. Relation to tumour growth and immunoglobulin levels in vivo Int. J. Cancer 28:1-9
272. 1981 Suppressor cell activity in melanoma patients. II: Concanavalin-A induced suppressor cells inrelation to tumour growth and suppressor T cell subsets Int. J. Cancer 28:11-15
273. 1981 Reactivity of antisera to antigens of C type viruses with leukocytes from patients with acute leukaemia. Pathology 13:289
274. 1981 Developments in immune complex therapy and its application to cancer Human Cancer Immunology, Eds. Serrou and Rosenfeld, North Holland, p.135-166
275. 1981 Developments in immune complex therapy and its application to cancer “Human Cancer Immunology”. Eds. Serrou and Rosenfeld, North Holland, p. 135-166
276. 1981 Monitoring tumour growth by detection of melanoma antigens in sera using leukocyte dependent antibody inhibition assays. Cancer Immunol. Immunotherapy 10:67.
277. 1981 Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2 Int. J. Cancer 28:695-703.
278. 1980 Release of factors inhibiting cell division from cultured tumour cells Clin. Exp. Immunol. 40:168
279. 1980 Characterization of an inhibitor of cell division released in tumour cell cultures Clin. Exp. Immunol. 41:487
280. 1980 Prognostic significance of expression of antigens on melanoma cells Cancer Immunol. Immunotherapy 9:233
281. 1980 Fungal retinitis: A case of torulopsis glabrate infection treated with miconazole Brit. J. Ophthal. 65:672
282. 1980 Tumour related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patient Int. J. Cancer 25:187
283. 1979 Natural killer cells – A new cytotoxic mechanism against tumours. Aust. N.Z. J. Med. 9:464
284. 1979 Leukocyte-dependent antibody assays in melanoma patients Immunodiagnosis of Human Cancer, Ed. Herberman, Elsevier North Holland, p.599
285. 1979 Natural killer cells – A new cytotoxic mechanism against tumours Aust. N.Z. J. Med. 9:464
286. 1979 Type 2 (Cytotoxic type) allergic drug reactions. Thrombocytopenia and haemolytic anaemia Aust. J. Hosp. Pharmacy 9:51
287. 1979 Leukocyte-dependent antibody assays in melanoma patients “Immunodiagnosis of Human Cancer”. Ed. Herberman. Elsevier, North Holland, p. 559
288. 1979 Detection of a small molecular weight antigen on melanoma cells by a human antiserum in leukocyte-dependent antibody assays Brit. J. Cancer 40:615.
289. 1979 Low natural killer cell activity in familial melanoma patients and their relatives Brit. J. Cancer 40:113
290. 1979 Nephelometric detection of circulating immune complexes using monoclonal rheumatoid factor J. Immunol. Methods 29:311
291. 1979 Low natural killer cell activity and immunoglobulin levels associated with smoking in human subjects Int. J. Cancer 23:603.
292. 1979 Inhibition of normal human granulopoiesis in vitro by non-B, non-T lymphocytes Brit. J. Haematol. 45:451
293. 1979 Quinidine hypersensitivity and lymphocyte transformation test Med. J. Aust. 1:246.
294. 1979 Demonstration of blood group-like antigens on the T lymphocytes of acute leukaemia patients Clin. Exp. Immunol. 39:403-410
295. 1979 Relationship of natural killer cell activity to rhesus antigen in human subjects Brit. J. Cancer 9:234
296. 1978 Analysis of serum blocking activity against melanoma LDA Int. J. Cancer 21:578
297. 1978 Sequential changes in leukocyte-dependent antibody activity in melanoma patients Europ. J. Cancer 14:629.
298. 1978 Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients Brit. J. Cancer 37:505
299. 1978 Removal of serum blocking factors against melanoma LDA by plasmapheresis Aust. & N.Z. J. Surg. 48:26.
300. 1977 Blocking factors against leukocyte-dependent melanoma antibody in the sera of melanoma patients Brit. J. Cancer 36:7
301. 1977 Enhanced osteosarcoma growth produced in rats by osteosarcoma allografts Brit. J. Cancer 35:86
302. 1977 Previous pregnancy as a protective factor against death from melanoma Lancet 1:451
303. 1977 Recent views on tumour antigens and their relationship to host defence mechanisms Aust. N.Z. J. Med. 7:526
304. 1977 Immunotherapy of solid tumours Aust. N.Z. J. Surg. 47:701
305. 1977 Recent views on tumour antigens and their relationship to host defence mechanisms Aust. N.Z. J. Med. 7:526
306. 1977 Detection of carcino-embryonic-like antigen on melanoma cells by leukocyte-dependent antibody assays Brit. J. Cancer 36:445
307. 1976 Characterization of effector cells in human blood Clin. Exp. Immunol. 23:140
308. 1976 Characteristics of lymphoma induced by radiotherapy Clin. Exp. Immunol. 23:200.
309. 1976 Effector cells and specificity of cell-mediated cytotoxicity against human melanoma cell lines “Pigment Cell” 2:191.
310. 1976 II. The effects of azathioprine on lymphoid cell populations in a double-blind trial in ulcerative colitis Clin. Exp. Immunol. 24:249
311. 1976 New approaches in immunotherapy (Comment) Med. J. Aust. 1:83
312. 1976 Antigens on melanoma cells detected by leukocyte-dependent antibody assays of human melanoma antisera Int. J. Cancer 18:564
313. 1976 Anti-leukaemia effect as a bystander effect of graft-versus-host reaction Brit. J. Cancer 33:370.
314. 1976 Antibody-dependent, cell-mediated cytotoxicity against melanoma cells induced by plasmapheresis Lancet 1:825.
315. 1975 Specificity of cell-mediated cytotoxicity against human melanoma lines. Evidence for “non-specific” killing by activated T cells Int. J. Cancer 16:173
316. 1975 Comparison of 51Cr release and microcytotoxicity assays against human melanoma cells. Int. J. Cancer 16:164
317. 1974 Macrophage eosinophil interactions in the inflammatory response to Trichinella Spiralis Blood 44:131
318. 1973 Cytotoxicity against human leukaemia cells. I. Demonstration of antibody dependent lymphocyte killing of human allogeneic myeloblasts Clin. Exp. Immunol. 14:159
319. 1973 Macrophage-dependent protection of tumour cells Immunol. 24:385
320. 1973 The protective effect of antisera against leukaemia in vivo. A re-appraisal. Brit. J. Cancer 28:11 (suppl. I).
321. 1973 Lymphocyte-dependent antibody. A new look at anti-serum therapy of leukaemia Nature 244:22
322. 1973 Thymus-dependent cytotoxic lymphocytes in rat Europ. J. Immunol
323. 1973 Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia Brit. Med. J. 2:395
324. 1973 Macrophage effector function Transplantation 15:282-290
325. 1973 Effects of anti-cancer agents on immunological status Brit. J. Cancer 29:254 (Suppl. I)
326. 1973 Lymphocyte-dependent antibody against human transplantation antigen Transplantation 16:9
327. 1972 Two unconventional mechanisms for immunological enhancement Trans. Proc. 4:277
328. 1971 The separation and 51Cr labelling of human lymphocytes with in vivo studies of survival and migration Blood 32:360


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.